{
    "pubmed_id": 35589681,
    "study_identifier": "PMID35589681_study-01",
    "study_name": "SARS-CoV-2 transmission and impacts of unvaccinated-only screening in populations of mixed vaccination status",
    "publication_title": "SARS-CoV-2 transmission and impacts of unvaccinated-only screening in populations of mixed vaccination status",
    "study_objective": "To evaluate the spread of SARS-CoV-2 in populations of mixed vaccination status, focusing on three critical questions. First, how do vaccinated and unvaccinated populations each contribute to community spread and hospitalizations, second, how do testing-based screening programs focused on unvaccinated individuals alone affect community spread and hospitalizations? third,  how effective are delta-era screening strategies likely to be against variants with higher breakthrough and reinfection rates?",
    "study_description": "Screening programs that test only the unvaccinated population have been proposed and implemented to mitigate SARS-CoV-2 spread, implicitly assuming that the unvaccinated population drives transmission. To evaluate this premise and quantify the impact of unvaccinated-only screening programs, we introduce a model for SARS-CoV-2 transmission through which we explore a range of transmission rates, vaccine effectiveness scenarios, rates of prior infection, and screening programs. We find that, as vaccination rates increase, the proportion of transmission driven by the unvaccinated population decreases, such that most community spread is driven by vaccine-breakthrough infections once vaccine coverage exceeds 55% (omicron) or 80% (delta), points which shift lower as vaccine effectiveness wanes. Thus, we show that as vaccination rates increase, the transmission reductions associated with unvaccinated-only screening decline, identifying three distinct categories of impact on infections and hospitalizations. More broadly, these results demonstrate that effective unvaccinated-only screening depends on population immunity, vaccination rates, and variant.",
    "primary_institution_name": "University of Colorado Boulder",
    "study_personnel": [
        {
            "personnel_id": "PMID35589681_personnel-01",
            "honorific": "",
            "last_name": "Larremore",
            "first_name": "Daniel",
            "suffixes": "",
            "organization": "University of Colorado Boulder",
            "orchid_id": "",
            "email": "daniel.larremore@colorado.edu",
            "seronet_title_in_study": "SeroNet Investigator",
            "role_in_study": "Investigator",
            "site_name": "University of Colorado Boulder"
        },
        {
            "personnel_id": "PMID35589681_personnel-02",
            "honorific": "",
            "last_name": "Middleton",
            "first_name": "Casey",
            "suffixes": "",
            "organization": "University of Colorado Boulder",
            "orchid_id": "",
            "email": "Casey.Middleton@colorado.edu",
            "seronet_title_in_study": "SeroNet Investigator",
            "role_in_study": "Investigator",
            "site_name": "University of Colorado Boulder"
        }
    ],
    "study_file": [
        {
            "study_file_name": "41467_2022_30144_MOESM1_ESM.pdf",
            "study_file_description": "Supplementary data",
            "study_file_type": "Study Data"
        },
        {
            "study_file_name": "PMID35589681_v1.2.4.xlsm",
            "study_file_description": "Completed curation of the study into SeroNet Registry Template which includes SeroNet Study Descriptors.",
            "study_file_type": "Study Summary Description"
        }
    ],
    "study_link": [
        {
            "link_name": "Github",
            "value": "https://zenodo.org/badge/latestdoi/419096560"
        }
    ],
    "research_focus": "Infection Response",
    "study_type": "Epidemiological Research",
    "keyword": [
        "COVID-19 Vaccines",
        "COVID-19 epidemiology",
        "COVID-19 prevention & control",
        "Hospitalization",
        "Humans",
        "Postoperative Complications",
        "SARS-CoV-2",
        "Vaccination"
    ],
    "clinical_study_design": "Other",
    "in_silico_model_type": "Epidemiological Model",
    "protocol": {
        "protocol_id": "PMID35589681_protocol-01",
        "protocol_file_name": "PMID35589681_protocol-01.txt",
        "protocol_name": "PMID35589681_protocol-01",
        "protocol_description": "Study Protocol",
        "protocol_type": "Study Protocol"
    },
    "reported_health_condition": [
        "Covid-19"
    ],
    "sars_cov_2_vaccine_type": [
        "N/A"
    ],
    "clinical_outcome_measure": "SARS-CoV-2 transmission",
    "enrollment_start_date": "",
    "enrollment_end_date": "",
    "number_of_study_subjects": "",
    "age_unit": "Years",
    "minimum_age": "",
    "maximum_age": "",
    "study_human_cohort": [
        {
            "arm_id": "PMID35589681_human_subject-01",
            "arm_name": "Vaccinated Group (V)",
            "study_population_description": "Vaccinated group from the 20,000 individuals who were enrolled for the SEIR analysis",
            "arm_type": "Vaccination",
            "ethnicity": [
                "Not Specified"
            ],
            "race": [
                "Not Specified"
            ],
            "race_specify": [],
            "description": "",
            "sex_at_birth": [
                "Not specified"
            ],
            "age_event": "Not Specified",
            "subject_phenotype": "",
            "assessment_name": [],
            "study_location": [
                "US: Colorado"
            ],
            "measured_behavioral_or_pyschological_factor": [],
            "measured_social_factor": [],
            "sars_cov_2_symptoms": [],
            "assessment_clinical_and_demographic_data_provenance": [],
            "assessment_demographic_data_types_collected": [],
            "sars_cov_2_history": [
                "Vaccinated"
            ],
            "sars_cov_2_vaccine_type": [
                "n/a"
            ],
            "covid_19_disease_severity": [],
            "post_covid_19_symptoms": [],
            "covid_19_complications": []
        },
        {
            "arm_id": "PMID35589681_human_subject-02",
            "arm_name": "Unvaccinated Group (U)",
            "study_population_description": "Unvaccinated group from the 20,000 individuals who were enrolled for the SEIR analysis",
            "arm_type": "Observational",
            "ethnicity": [
                "Not Specified"
            ],
            "race": [
                "Not Specified"
            ],
            "race_specify": [],
            "description": "",
            "sex_at_birth": [
                "Not specified"
            ],
            "age_event": "Not Specified",
            "subject_phenotype": "",
            "assessment_name": [],
            "study_location": [
                "US: Colorado"
            ],
            "measured_behavioral_or_pyschological_factor": [],
            "measured_social_factor": [],
            "sars_cov_2_symptoms": [],
            "assessment_clinical_and_demographic_data_provenance": [],
            "assessment_demographic_data_types_collected": [],
            "sars_cov_2_history": [
                "Not vaccinated"
            ],
            "sars_cov_2_vaccine_type": [
                "n/a"
            ],
            "covid_19_disease_severity": [],
            "post_covid_19_symptoms": [],
            "covid_19_complications": []
        }
    ],
    "study_model_cohort": [],
    "planned_visit": [
        {
            "visit_id": "PMID35589681_visit-01",
            "visit_name": "Model",
            "visit_order_number": 1,
            "visit_min_start_day": 0,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        }
    ],
    "experiment": [
        {
            "arm_id": [
                "PMID35589681_human_subject-01"
            ],
            "associated_first_planned_visit_id": [
                "PMID35589681_visit-01"
            ],
            "assay_type": "",
            "experiment_name": "",
            "experiment_results_file_name": "na",
            "biospecimen_type": [
                "Other"
            ],
            "biospecimen_collection_point": [
                "n/a"
            ],
            "sars_cov_2_antigen": [
                "n/a"
            ],
            "assay_use": "",
            "manufacture": "components from multiple manufacturers",
            "catalog_number": "",
            "virus_target": [],
            "antibody_isotype": [
                "Other"
            ],
            "reporting_units": "",
            "assay_reporting_format": ""
        }
    ],
    "geriatric_subjects": "Not Specified",
    "pediatric_subjects": "Not Specified",
    "pregnant_subjects": "Not Specified",
    "sars_cov_2_antibodies_measured": "Yes",
    "survey_instrument_shared": "Not Specified",
    "who_disease_severity_scale_used": "Not Specified",
    "inclusion_exclusion": [
        {
            "inclusion_exculusion_id": "PMID35589681_inexcl-01",
            "inclusion_criterion": "SARS-CoV-2 Antibodies Measured",
            "inclusion_criterion_category": "inclusion"
        },
        {
            "inclusion_exculusion_id": "PMID35589681_inexcl-02",
            "inclusion_criterion": "Vaccinated individuals",
            "inclusion_criterion_category": "inclusion"
        },
        {
            "inclusion_exculusion_id": "PMID35589681_inexcl-03",
            "inclusion_criterion": "Unvaccinated individuals",
            "inclusion_criterion_category": "inclusion"
        }
    ],
    "suggestions": [
        "affect",
        "alone",
        "antibodies",
        "associated",
        "assuming",
        "boulder",
        "breakthrough",
        "broadly",
        "categories",
        "colorado",
        "community",
        "contribute",
        "coverage",
        "covid-19",
        "covid-19 epidemiology",
        "covid-19 prevention & control",
        "covid-19 vaccines",
        "critical",
        "decline",
        "decreases",
        "delta",
        "delta-era",
        "demonstrate",
        "depends",
        "distinct",
        "driven",
        "drives",
        "effective",
        "effectiveness",
        "epidemiological",
        "evaluate",
        "exceeds",
        "explore",
        "find",
        "first",
        "focused",
        "focusing",
        "higher",
        "hospitalization",
        "hospitalizations",
        "humans",
        "identifying",
        "immunity",
        "impact",
        "impacts",
        "implemented",
        "implicitly",
        "increase",
        "individuals",
        "infection",
        "infections",
        "introduce",
        "likely",
        "lower",
        "measured",
        "mitigate",
        "mixed",
        "model",
        "n/a",
        "omicron",
        "points",
        "population",
        "populations",
        "postoperative complications",
        "premise",
        "prior",
        "programs",
        "proportion",
        "proposed",
        "quantify",
        "questions",
        "range",
        "rates",
        "reductions",
        "reinfection",
        "research",
        "response",
        "results",
        "sars-cov-2",
        "scenarios",
        "screening",
        "second",
        "shift",
        "show",
        "spread",
        "status",
        "strategies",
        "test",
        "testing-based",
        "third",
        "three",
        "thus",
        "transmission",
        "university",
        "unvaccinated",
        "unvaccinated-only",
        "vaccinated",
        "vaccination",
        "vaccine",
        "vaccine-breakthrough",
        "variant",
        "variants",
        "wanes"
    ]
}